findmyKOL
Clinical trialNCT01040832CompletedPhase 2Interventional

EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

SponsorEMD SeronoEnrollment107Squamous Cell Carcinoma of the Head and Neck Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Philip Breitfeld, MD

    EMD Serono, Inc., Rockland MA, a subsidiary of Merck KGaA, Darmstadt, Germany

    Study Director

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

35 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Belgium
  • Research Site

    Brussels, Belgium

  • Uz Gent

    Ghent, Belgium

  • Research Site

    Wilrijk, Belgium

  • Cliniques Universitaires Mont-Godinne

    Yvoir, Belgium

Czechia
  • Research Site

    Brno, Czechia

  • Research Site

    Kladno, Czechia

  • Research Site

    Pardubice, Czechia

  • Ustav Radiacni Onkologie Fakultni Nemacnice Na Bulovce

    Prague, Czechia

France
  • Research Site

    Montpellier, France

  • Research Site

    Villejuif, France

Hungary
  • Research Site

    Győr, Hungary

  • Research Site

    Kecskemét, Hungary

  • Research Site

    Miskolc, Hungary

  • Research Site

    Nyiregyahaza, Hungary

  • Szegedi Tudomayegyetem Altalanos Orvostudomanyi Kar Onkoterapias Klinika

    Szeged, Hungary

  • Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet

    Szolnok, Hungary

  • Zala Megyei Kohaz Kulsokorhaz Onkologia Osztaly

    Zalaegerszeg, Hungary

Poland
  • Spzoz Centrum Onkologi Liemi Lubelskiej, Ii Odzial Radioterapiii Z Pododdzialem Chemioterpii

    Lublin, Poland

  • Zaklad Opleki Zdrowotnej Mswia Z Warminsko-Mazurskim Centrum Onkologil, Oddziat Chemioterapli

    Olsztyn, Poland

  • Centrum Onkologi - Instytut Im. Marii Sklodowskiej-Curie, Klinika Nowotworow Glowy I Szyi (nci)

    Warsaw, Poland

Slovakia
  • Onkologicky Ustav Sv. Alzbety

    Bratislava, Slovakia

  • Nemocnice S Poliklinikou Zilina

    Žilina, Slovakia

United Kingdom
  • Velindre Cancer Centre

    Cardiff, United Kingdom

  • Research Site

    Conventry, United Kingdom

  • Mhcw

    Coventry, United Kingdom

  • St. James' University Hospital

    Leeds, United Kingdom

  • Research Site

    London, United Kingdom

  • the Christie Nhs Ft

    Manchester, United Kingdom

  • Research Site

    Newcastle upon Tyne, United Kingdom

  • Weston Park Hospital

    Sheffield, United Kingdom

  • Southampton University Hospitals Nhs Trust

    Southampton, United Kingdom

United States
  • University of Colorado Cancer Center

    Aurora, Colorado, United States

  • University of Kentucky, Markey Cancer Center

    Lexington, Kentucky, United States

  • Mgh Massachusetts General Hospital

    Boston, Massachusetts, United States

  • Montefiore Medical Center Oncology

    The Bronx, New York, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Dec 2009
Primary completion
31 Jan 2012
Completion
Last update posted
30 Jan 2017
Registered enrollment
107
Registry id
NCT01040832

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.